Keywords
smoking habit, metabolic syndrome, smokers, hypertension, cardiovascular risk.
smoking habit, metabolic syndrome, smokers, hypertension, cardiovascular risk.
We thank the reviewer for evaluating and commenting on our manuscript.
1. Grammatical adjustments were made according to the suggestions.
2. The JNC-7 description was deleted.
3. In the first paragraph of the discussion, the main findings were added.
4. The relation between masked hypertension and smoking was added, as a hypothesis of the findings related to hypertension in our study.
To read any peer review reports and author responses for this article, follow the "read" links in the Open Peer Review table.
Smoking is one the main causes of morbidity and mortality in the working-age population; it is responsible for approximately 7.2 million deaths per year1. This constitutes a major public health issue. Almost one-third of the world population older than 15 years of age smokes2, with a global prevalence of 21.2% in developing countries3. In the Americas, the prevalence in the general adult population is 17.1%4; however, this varies among different countries, with Chile having the highest (38.9%) and Panama the lowest (7.4%) rates4. Venezuela is a country with one of the highest prevalence (33.9%)5, with a frequency of 14.8% in Maracaibo City in recent studies6.
Smoking habit is a major modifiable risk factor for developing non-communicable diseases2, including cardiovascular disease (CVD) and type 2 diabetes mellitus (DM2)7. A growing body of evidence suggests that before the onset of these two diseases, cigarette smoking favors the appearance of metabolic syndrome (MS)8,9 high blood pressure, dyslipidemia, obesity and high blood glucose10–14. Main contributors for this association include the presence of dyslipidemia and central obesity15.
The physiopathology of the relationship between cigarette smoking and MS comes from a decrease in peripheral insulin sensitivity, lipoproteins metabolism alterations and endothelial dysfunction, all present in smoking individuals16. Until now, epidemiological published results are not definitive in showing the association between cigarette smoking and MS. On the other hand, it is not certain whether this association is caused by other behavioral patterns and unhealthy habits of patients with cardiometabolic diseases17. Thus, the aim of this study was to evaluate the relationship between smoking habit and MS components in the adult population from Maracaibo City, Venezuela.
The Maracaibo city MS prevalence study (MMSPS) was a cross-sectional, descriptive study performed in Maracaibo, Venezuela. It was designed to provide estimations about the presence of MS and associated cardiovascular risk factors in the adult population during the period between May 2007 and December 2009. The study method was reported previously18. The most important aspects of the protocol are presented here. Maracaibo city was divided into parishes, which were sampled proportionally through a multistage random sampling, defining conglomerates in two phases: In the first phase, the conglomerates represented the sectors of the 18 parishes, selecting 4 areas per parish by means of simple random sampling; in the second phase, the conglomerates were represented by the neighborhood of each chosen area, to which a random number was assigned. To evaluate smoking habit in this sub-study, 18 subjects were excluded: 9 because of inconsistencies about when they started smoking; the other 9 subjects because they smoked cigar types that were different to cigarettes. Finally, a total of 2212 subjects were evaluated. The study was approved by the Bioethics Committee of the Endocrine and Metabolic Research Center – University of Zulia (approval number: BEC-006-0305). This ethical approval included all future studies that used the data from the MMSPS. All participants signed an informed consent form before being questioned and physically examined by a trained team.
Every subject in the study underwent a medical examination performed by trained personnel to obtain a full medical history. During the anamnesis, past medical and family history of endocrine and metabolic disorders was collected; including age, race, marriage status, education and socioeconomic status. The latter was measured using the Graffar scale modified by Mendez-Castellano and De Mendez19.
The auscultatory method was performed to measure arterial pressure, using an adequate calibrated and validated sphygmomanometer. Korotkoff phases I and V were used to measure systolic and diastolic pressures, respectively. Subjects remained sitting still for 15 minutes before assessment, with both feet on the ground. A total of 3 measurements per day were taken in 15 minute intervals, for 2 days consecutively. Anthropometric measures were taken using a height rod that had been previously calibrated and placed on a flat surface. Weight was measured using a digital weighing scale (Tanita, TBF-310 GS Body Composition Analyzer; Tokyo, Japan), with the patient wearing light clothes and no shoes. The body mass index (BMI) was calculated applying the Quetelec formula (weight/height2), and classified according to the WHO classification20, as follows: normal weight (<25 Kg/m2), overweight (25.0–29.9 Kg/m2), obese (≥30.0 Kg/m2). Abdominal circumference was measured using a plastic measuring tape, graded in centimeters and millimeters, in a spot equidistant to the lower ribcage and the anterior-superior iliac spine, according to the United States National Institute of Health protocol21.
Subjects were asked about smoking habit presence and duration, being categorized as: a) current smoker, any subject who had smoked more than 100 cigarettes in his/her lifetime, is currently smoking, or less than 1 year had passed after he/she quit smoking; b) Former smoker: any subject who has quit smoking for more than 1 year; c) non-smoker, any subject who has never smoked or had smoked less than 100 cigarettes in his/her lifetime6. Smoking intensity was assessed posteriorly, according to number of cigarettes per day. It was divided in the following tertiles: T1 <3 cigarettes/day; T2 = 3–9 cigarettes/day; and T3 ≥10 cigarettes/day.
Physical activity was evaluated using the International Physical Activity Questionnaire22. It takes into account four elements of evaluation: physical activity in transport, work, domestic and gardening, and leisure time. To quantify time investment on each element, subjects were classified in quintiles. The final scoring was reported using metabolic equivalents (METs)-min/week on each item; any subject with 0 METs was considered as physically inactive.
Subjects with ≥1 MET were classified in quintiles according to gender, resulting in six categories for physical activity: physical inactivity (MET = 0), very low (Q1), low (Q2), moderate (Q3), high (Q4), and very high (Q5) physical activity. Leisure time was classified as: a) Q1 or very low physical activity, <296.999 METs for men and <230.999 METs for women; b) Q2 or low physical activity, 297.000–791.999 METs for men and 231.000-445.499 METs for women; Q3 or moderate physical activity, 792.000–1532.399 METs for men and 445.500-742.499 METs for women; Q4 or high physical activity, 1532.400–2879.999 MET for men and 742,500–1798.499 METs for women; and e) Q5 or very high physical activity, ≥2879.000 METs for men and ≥1798.500 METs for women. For alcohol consumption, any subject that drinks ≥1 gram daily was considered as a “drinker”23.
After 8 hours of fasting, a blood sample was taken from the cubital vein, and was centrifuged to obtain the serum. Serum levels of glucose (catalog number REF-10123), total cholesterol (catalog number REF-10015) and triacylglycerides (TAG) (catalog number REF-10163) were determined using enzymatic–colorimetric kits (Human Gesellschaft für Biochemica und Diagnostica mbH) and a specialized computer system. Glycemic status was classified according to ADA 2017 criteria in normal glucose (basal glucose, <100 mg/dl), impaired fasting glucose (basal glucose, 100–125 mg/dl) and DM2 (≥126 mg/dl)24. Serum hs-C reactive protein (hs-CRP) levels were quantified using immunoturbodimetric assays (Human Gesellschaft für Biochemica und Diagnostica mbH. (catalog number REF-11544), setting the cutoff point at ≥0,765 mg/l25.
Basal insulin serum levels were determined using a commercial kit (catalog number EIA-2935) based on the ELISA method (DRG International, Inc.), with a detection limit of <1 mU/l. Insulin resistance (IR) was calculated using software (HOMA-Calculator v2.2.2) supplied by the Oxford Centre for Diabetes, Endocrinology and Metabolism; the cutoff-point for HOMA2-IR was 2.0026.
MS diagnosis was made using the proposed criteria from the IDF and AHA/NHLBI in 200927. It requires three or more of the following components to achieve a diagnosis: 1) TAG ≥150 mg/dl; 2) high-density lipoprotein–cholesterol (HDL-C) <40 mg/dl for men or <50 mg/dl for women; 3) basal glucose levels ≥100 mg/dl, or a previous diagnosis of DM2 or use of an antidiabetic drug; 4) arterial pressure ≥130/85 mmHg, or a previous diagnosis of hypertension or use of an antihypertensive drug; 5) abdominal circumference with cutoff points adapted for our population, which are ≥91 for women and ≥98 cm for men28.
Qualitative variables were expressed in absolute and relative frequencies. The relationship between these was examined with a χ2 test and the difference in proportions using a Z-test. Quantitative variables were expressed in arithmetic means ± standard deviations, with prior analysis using Geary’s test. Variables without a normal distribution were submitted to logarithmic transformation with posterior normality test. Multiple logistic regression models were made to estimate odds ratios (OR) and 95% confidence intervals (95% CI); they were used for the presence of MS and each of its components, adjusted for gender, age, ethnic group, marital status, education level, socioeconomic status, working status, alcohol consumption, BMI categories, insulin resistance and smoking habit. On another model, smoking intensity was assessed dividing consumption in tertiles (T1 <3 cigarettes/day; T2 = 3–9 cigarettes/day; and T3 ≥10 cigarettes/day). Data were analyzed by using SPSS v.21 for Windows (IBM SPSS), and considering statistically significant results when p<0,05.
A total of 2212 individuals were studied, of whom 52.7% (n=1166) were women. The mean age ± SD was 39.27±15.38 years, and the most frequently occurring age group was 30–49 years (38.5%; n=851). For smoking habit, 14.8% were smokers (n=328), 15.4% former smokers (n=340) and 69.8% were non-smokers (n=1544). The prevalence of MS was 35.7% (n=935) in the sample. The most frequent MS components were low HDL-C (57.6%; n=1275) and abdominal obesity (48.5%; n=1072). Other general characteristics can be found in Table 1.
Variable | Female (n=1166) | Male (n=1046) | Total (n=2212) | |||
---|---|---|---|---|---|---|
n | % | n | % | n | % | |
Age (years) | ||||||
<30 | 349 | 29.9 | 410 | 39.2 | 759 | 34.3 |
30–49 | 464 | 39.8 | 387 | 37.0 | 851 | 38.5 |
≥50 | 353 | 30.3 | 249 | 23.8 | 602 | 27.2 |
Marital status | ||||||
Single | 495 | 42.5 | 455 | 43.5 | 950 | 42.9 |
Married | 427 | 36.6 | 446 | 42.6 | 873 | 39.5 |
Other | 244 | 20.9 | 145 | 13.9 | 389 | 17.6 |
Socioeconomic status | ||||||
Stratus I: high class | 17 | 1.5 | 19 | 1.8 | 36 | 1.6 |
Stratus II: middle-high class | 206 | 17.7 | 204 | 19.5 | 410 | 18.5 |
Stratus III: middle class | 432 | 37.0 | 440 | 42.1 | 872 | 39.4 |
Stratus IV: Working class | 446 | 38.3 | 344 | 32.9 | 790 | 35.7 |
Stratus V: extreme poverty | 65 | 5.6 | 39 | 3.7 | 104 | 4.7 |
Working status | ||||||
Employed | 527 | 45.2 | 757 | 72.4 | 1284 | 58.0 |
Unemployed | 639 | 54.8 | 289 | 27.6 | 928 | 42.0 |
Education | ||||||
Illiterate | 33 | 2.8 | 19 | 1.8 | 52 | 2.4 |
Primary school | 237 | 20.3 | 112 | 10.7 | 349 | 15.8 |
High school | 516 | 44.3 | 519 | 49.6 | 1035 | 46.8 |
Higher education | 380 | 32.6 | 396 | 37.9 | 776 | 35.1 |
Ethnic group | ||||||
Mixed | 873 | 74.9 | 807 | 77.2 | 1680 | 75.9 |
White-Hispanic | 189 | 16.2 | 159 | 15.2 | 348 | 15.7 |
Afro-Venezuelan | 30 | 2.6 | 36 | 3.4 | 66 | 3.0 |
Indigenous American | 62 | 5.3 | 43 | 4.1 | 105 | 4.7 |
Other | 12 | 1.0 | 1 | 0.1 | 13 | 0.6 |
Smoking habit | ||||||
Non smoker | 878 | 75.3 | 666 | 63.7 | 1544 | 69.8 |
Current smoker | 134 | 11.5 | 194 | 18.5 | 328 | 14.8 |
Former smoker | 154 | 13.2 | 186 | 17.8 | 340 | 15.4 |
Leisure time physical activity | ||||||
Inactive | 832 | 71.4 | 529 | 50.9 | 1361 | 61.7 |
Very low | 67 | 5.7 | 99 | 9.5 | 166 | 7.5 |
Low | 62 | 5.3 | 102 | 9.8 | 164 | 7.4 |
Moderate | 64 | 5.5 | 103 | 9.9 | 167 | 7.6 |
High | 72 | 6.2 | 92 | 8.8 | 164 | 7.4 |
Very high | 69 | 5.9 | 115 | 11.1 | 184 | 8.3 |
Alcohol consumption | 219 | 18.8 | 505 | 48.3 | 724 | 32.7 |
Metabolic syndrome† | 470 | 40.3 | 465 | 44.5 | 935 | 42.3 |
Metabolic syndrome‡ | 391 | 33.5 | 398 | 38.0 | 789 | 35.7 |
Low HDL† | 747 | 64.1 | 528 | 50.5 | 1275 | 57.6 |
High TAG† | 268 | 23.0 | 343 | 32.8 | 611 | 27.6 |
Hyperglycemia† | 301 | 25.8 | 317 | 30.3 | 618 | 27.9 |
High blood pressure† | 406 | 34.8 | 447 | 42.7 | 853 | 38.6 |
Abdominal obesity† | 920 | 78.9 | 741 | 70.8 | 1661 | 75.1 |
Abdominal obesity‡ | 569 | 48.8 | 503 | 48.1 | 1072 | 48.5 |
Smoking habit in accordance to MS components could be seen in Table 2. It shows a statistically significant association between cigarette smoking and having MS (χ2=39.285; p<0.001) with a greater percentage of individuals with MS in former smokers (47.9%) and current smokers (42.1%) than in non-smokers (31.6%), p<0.05.
Maracaibo, Venezuela.
Smoking status | MS‡ | High TAG† | Abdominal obesity‡ | Hyperglycemia† | Low HDL-C† | High BP† | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | n | % | |
Nonsmoker | 488 | 31.6 | 364 | 23.6 | 687 | 44.5 | 400 | 25.9 | 878 | 56.9 | 569 | 36.9 |
Current Smoker | 138 | 42.1 | 121 | 36.9 | 171 | 52.1 | 104 | 31.7 | 201 | 61.3 | 119 | 36.3 |
Former Smoker | 163 | 47.9 | 126 | 37.1 | 214 | 62.9 | 114 | 33.5 | 196 | 57.6 | 165 | 48.5 |
MS, Metabolic Syndrome; TAG, triacylglycerides; HDL-C, high-density lipoprotein-cholesterol; BP, blood pressure.
MS: χ2= 39.285 (p<0.001); High TAG: χ2= 41.886 (p<0.001); Abdominal Obesity: χ2= 40.039 (p<0.001); Hyperglycemia: χ2= 10.759 (p=0.005); Low HDL-C levels: χ2= 2.160 (p=0.340); High Blood Pressure: χ2= 16.883 (p<0.001). †According to IDF and AHA-NHLBI-ISO 200927. ‡ According to The Maracaibo City Metabolic Syndrome Study28: WC ≥98cm for men; ≥91cm for women.
Each component of the MS was analyzed in relation to smoking. A higher percentage of individuals with high TAG were former (37.1%) and current (36.9%) smokers, compared with non-smokers (23.6%) (χ2=41.886; p<0.001). The same happened for abdominal obesity in former smokers (62.9%) and current smokers (52.1%) (χ2=40.039, p<0.001). A high percentage of former smokers presented hyperglycemia (33.5% vs 25.9%; χ2=10.759; p<0.005) and high blood pressure (48.5 vs 36.9%; χ2=16.88; p<0.001) in comparison to nonsmokers. No statistical association was found between low HDL-C and smoking status.
Comparing smoking habit with the number of MS criteria (Figure 1), a statistically significant association was observed (χ2=49.249, p<0.001). The highest percentages were with nonsmokers who met 0 criteria (76.31%) and 1 criterion (76.77%). However, the greatest prevalence of smokers was observed in subjects who met 4 (16.96%) and 5 (20%) criteria.
In Table 3, models of multivariate logistic regression are shown for the diagnosis of MS and its components. An association between current smoking and increased risk of presenting with MS could be observed (OR, 1.54; 95% CI, 1.11–2.14; p=0.010); the same was true of high TAG serum levels (OR, 1.66; 95% CI, 1.23–2.23; p<0.001); abdominal obesity (OR, 1.54; 95% CI, 1.05–2.28; p=0.027) and low HDL-C levels (OR, 1.32; 95% CI, 1.01–1.74; p=0.046).
Smoking status | MS‡ | High TAG† | Abdominal Obesity‡ | Hyperglycemia† | Low HDL-C† | High BP† |
---|---|---|---|---|---|---|
OR (95% CI); p | OR (95% CI); p | OR (95%CI); p | OR (95%CI); p | OR (95%CI); p | OR (95%CI); p | |
Non- smokers | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
Current smokers | 1.54 (1.11–2.14); 0.010 | 1.66 (1.23–2.23); <0.001 | 1.54 (1.05–2.28); 0.027 | 1.13 (0.83–1.54); 0.408 | 1.32 (1.01–1.74); 0.046 | 0.70 (0.51–0.95); 0.025 |
Former smokers | 0.96 (0.70–1.31); 0.799 | 1.15 (0.86–1.53); 0.324 | 1.24 (0.85–1.81); 0.245 | 0.86 (0.64–1.16); 0.330 | 0.97 (0.74–1.26); 0.832 | 0.79 (0.58–1.06); 0.127 |
On the other hand, by assessing smoking intensity according to number of cigarettes per day (Table 4), an association between the consumption tertile and high serum TAG levels was observed (T3: OR, 1.51; 95% CI, 1.03–2.22; p=0.036). Also, an association was observed between smoking intensity and abdominal obesity (T3: OR, 2.05; 95% CI, 1.15–3.64; p=0.015). By contrast, an inverse relationship was observed with high blood pressure (T3: OR, 0.66; 95% CI, 0.44–0.99; p=0.045).
Smoking status | MS‡ | High TAG† | Abdominal Obesity‡ | Hyperglycemia† | Low HDL-C† | High BP† |
---|---|---|---|---|---|---|
OR (95%CI); p | OR (95%CI); p | OR (95%CI); p | OR (95%CI); p | OR (95%CI); p | OR (95%CI); p | |
Non-smoker | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
<3 cigarettes/day | 1.13 (0.79–1.62); 0.487 | 1.25 (0.90–1.73); 0.178 | 1.42 (0.94–2.13); 0.092 | 1.02 (0.72–1.42); 0.932 | 1.10 (0.82–1.47); 0.539 | 0.75 (0.54–1.06); 0.101 |
3–9 cigarettes/day | 1.25 (0.88–1.78); 0.208 | 1.41 (1.02–1.95); 0.035 | 1.11 (0.73–1.69); 0.620 | 1.01 (0.72–1.41); 0.968 | 1.24 (0.91–1.69); 0.166 | 0.81 (0.58–1.13); 0.210 |
≥10 cigarettes/day | 1.21 (0.78–1.88); 0.381 | 1.51 (1.03–2.22); 0.036 | 2.05 (1.15–3.64); 0.015 | 0.90 (0.61–1.35); 0.620 | 1.02 (0.70–1.49); 0.912 | 0.66 (0.44–0.99); 0.045 |
Cigarettes are composed of more than 1000 toxic and carcinogenic elements. Nicotine is the main alkaloid in tobacco; it constitutes 1.5% of the commercial cigarette weight and 95% of the total alkaloids present29. Despite its effects, cigarette smoking has spread all over the globe, becoming a leading cause of chronic and degenerative pathologies. In Latin America, its use has markedly increased since 1950, and is now considered the second most common cardiovascular risk factor, following high blood pressure30. This has led to an increase in cancer deaths and a drop in life expectation of 2–6 years31. In Maracaibo, high prevalence of cigarette smoking and MS has been observed, which may suggest an existing relationship between these variables6,32. The main finding in this report is the relationship between cigarette smoking and metabolic syndrome, being associated specially with low high-density lipoprotein-cholesterol, increased abdominal circumference and elevated triacylglyceride levels.
In this study, MS prevalence in current smokers was 42.1% in both genders and a greater probability of having MS than in nonsmokers was observed. Kang and Song in the Korea National Health and Nutrition Examination Survey (KHANES) reported similar results with a cross-sectional study with 11559 subjects. They evaluated smoking habit by looking for nicotine in urine samples; a greater risk for developing MS was observed in those subjects33. Likewise, Slagter et al.11 conducted a study in the Netherlands which included 59,467 subjects from both sexes. In that study, a higher prevalence of MS was observed in smokers (a dose-dependent relationship), and increased the risk of MS depended neither on BMI nor gender.
Sun et al.8 conducted a meta-analysis from multiple cohort studies and included 13 articles. In total, 56,691 subjects and 8688 cases from Asia, Europe and North America were included. They found that cigarette smoking actively increases the risk of having MS. The effects of smoking on the cardiovascular system could be caused by increased action of nicotinic receptors. Activation of nicotinic receptor could promote the release of neutransmitters and hormones such as vasopressin, CRH, ACTH, growth hormone, dopamine, serotonin, glutamate and GABA in the central nervous system, acetylcholine in the peripheral nervous system, and catecholamine and cortisol from the adrenal glands. All of these molecules affect metabolism and appetite regulation34.
The CKB cohort study35 included 487,527 adult subjects and reported that regular cigarette smoking was associated with a decrease in BMI and an increase in abdominal circumference in both men and women (they used an adjusted model for BMI). Similar results were reported from the FINRISK study36, which included 5817 Finnish adults; greater abdominal circumference was observed in overweight and obese women who smoke. Clair et al.37, in a cross-sectional study that included 6123 adult Caucasians from Switzerland, reported that both sexes had an increased risk of obesity according to the number of cigarettes they smoke per day. These results resemble those from the present study, where cigarette smoking was associated with increased abdominal obesity. This epidemiological behavior could be explained by the recent hypothesis of the association between cigarette smoking and a decrease in body weight, using the CHRNA3 genetic variant (rs1051730); establishing that smoking does not affect body fat distribution and the increase in localized visceral fat and in abdominal obesity are due to high cortisol plasma levels and insulin resistance, respectively38–40.
In this study, cigarette smoking represents a risk factor for having high TAG levels. Similar behavior was seen in the ICMR-INDIAB cross-sectional study41 of 16,607 adult individuals, which showed a positive correlation between high TAG levels and smoking. Ueyama et al.42 reported there was a positive association between smoking and high TAG levels in a study of 5959 Japanese individuals. This phenomenon could be explained by the fact that stimulation of the sympathetic nervous system produces the release of insulin antagonists. These antagonists, such as cortisol and growth hormone, increase lipolysis, leading to an elevation of free fatty acids in the blood8,40.
Low HDL-C levels were observed more frequent in smokers than nonsmokers in our study. Sun et al.43, in a cross-sectional study of 11,956 Chinese individuals, reported similar results by showing that current smokers had an increased risk of having low HDL-C levels. Takata et al.44, showed that in 32 individuals who were participating in an anti-smoking program using varenicline or transdermal nicotine patches, HDL-C levels, apolipoprotein AI and HDL subfractions did not change significantly according to therapeutic strategy used. In the same study, cholesterol efflux capacity and HDL inflammatory index improved significantly with the anti-smoking program (baseline cholesterol efflux capacity: 14.15±2.46% vs after smoking cessation cholesterol efflux capacity: 14.83±2.35%; p=0.01; baseline HDL inflammatory index: 1.13±0.31 vs after smoking cessation HDL inflammatory index: 0.98±0.18 %; p=0.01).
The inverse relationship between current cigarette smoking and high blood pressure observed in the present study is noteworthy. However, three decades ago cigarette smoking was globally reported as acutely increasing blood pressure, heart frequency and myocardial contractility45. This was thought to be caused by increased nicotinic activity on the sympathetic nervous system. Despite this, epidemiological evidence could not confirm the role of cigarette smoking in the development of elevated blood pressure46. On the other hand, diverse evidence suggests an inverse relationship between these factors. Kaneko et al.47, in a recent study of 1297 Japanese individuals without any history of high blood pressure, showed that cigarette smoking appeared to be a “protective” factor against blood pressure elevation. Onat et al.48 observed a similar pattern in a Turkish population. The inverse association between blood pressure and smoking habit could be related to the cigarette effect on weight loss, since obesity is associated with a high incidence of high blood pressure; explaining the rebound effect on blood pressure in obese subjects who stop smoking48; however, this study evidenced that smokers presented with more abdominal obesity than nonsmokers. Another theory to explain this behavior suggests that smokers show less response to psychological stress: many of them report a decrease in anxiety and stress when smoking a cigarette49. This may come from modifications to adrenal and cardiovascular responses to external stimuli caused by cigarette smoking; thus, stopping smoking would increase blood pressure50.
Leone51 reports a two-phase effect of cigarette smoking on arterial pressure: the first phase, without a determined duration, when there is a decrease in blood pressure; and the second phase, when the smoker develops elevated blood pressure from the toxic effects of carbon monoxide51. This finding shows the importance in chronologically assessing smoking habit duration. Despite this, smoking does not benefit to cardiovascular health, but increases the risk of cardiovascular disease, especially in men48. These are not the only contradictory findings in relation to tobacco use and the presence of hypertension, recently Gonzalez et al.52 reported in a population from The Andes region of Venezuela, an association between the "chimó" consumption (a smokeless tobacco preparation) and lower frequency of hypertension, suggesting that the occurrence of masked hypertension in tobacco users as a possible explanation-an issue that is highly probable given the prejudices known to patients when using these products. Therefore, analyses with ABMP are necessary to assess the effect of tobacco on blood pressure throughout the day.
Similarly, with the assessment of smoking intensity according to number of cigarettes per day, a direct relationship was found between the number of cigarettes smoked and an increased risk of high serum TAG levels and abdominal obesity, and an inverse relationship with hypertension; this was seen especially in heavy smokers (≥10 cigarette daily). In this sense, in a study performed by Chen et al.10, 1146 individuals showed a significant dose-response relationship between the number of cigarettes per day and high TAG levels. Data analysis from the KHANES study revealed an increased risk of obesity and central obesity with an increase in smoking habit intensity53. This relationship could be caused by the dose-dependent effect of nicotine on fatty acid metabolism and catecholamine release; also inducing increase in lipolysis, free fatty acids, VLDL, LDL levels, and visceral adipose tissue independent of weight gain or loss54.
In the present study, former smokers did not exhibit an increased risk of developing MS or its components when compared with non-smokers. Similar results were reported in Korea by Oh et al.55. The benefits to cardiovascular health from stopping cigarette smoking seem to depend on the following variables: first, the time since the subject stopped; and second, the length of time for which he/she was smoking and the quantity of cigarettes. A previous study showed that smoking 20 cigarettes daily increased the risk of developing MS for the next 10 years, whereas smoking 40 cigarettes daily increased the risk for the next 20 years56. This is why in the Maracaibo population it is necessary to conduct a cohort study on subjects who stopped smoking to evaluate the long term effects on cardiometabolic health.
Regarding the limitations of this study, its cross-sectional design makes it incapable of determining causality; it is also influenced by the subjectivity of its participants regarding the intensity and duration of their smoking habit. All of this should be considered in future studies.
In conclusion, the present study showed that smoking in our population represent a related factor with MS, and is individually associated with low HDL-C levels, increased abdominal circumference and high TAG levels. Former smokers did not show any increase in risk of present MS relative to non-smokers; despite this, future research studies should be conducted to evaluate how stopping cigarette smoking decreases cardiometabolic risk. Prevention measures focused on patients who smoke, especially anti-smoking counseling from medical personnel, could help to decrease any cigarette cardiometabolic consequences in the Maracaibo City population.
Dataset 1. Cigarette smoking and MS MMSPS dataset. DOI: 10.5256/f1000research.14571.d20185157
This study was funded by the Council of Scientific, Humanistic and Technological Development under No. CC-0437-10-21-09-10 and Fundacite-Zulia under No. FZ-0058-2007.
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Yes
References
1. González-Rivas J, Santiago R, Mechanick J, Nieto-Martínez R: Chimó, a Smokeless Tobacco Preparation, is Associated With a Lower Frequency of Hypertension in Subjects with Type 2 Diabetes. International Journal of Cardiovascular Sciences. 2017. Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Epidemiology, cross-sectional surveys, cardiometabolic risk factors
Is the work clearly and accurately presented and does it cite the current literature?
Partly
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
Yes
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
No
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 3 (revision) 11 Jan 19 |
read | |
Version 2 (revision) 22 May 18 |
read | |
Version 1 10 May 18 |
read |
Click here to access the data.
Spreadsheet data files may not format correctly if your computer is using different default delimiters (symbols used to separate values into separate cells) - a spreadsheet created in one region is sometimes misinterpreted by computers in other regions. You can change the regional settings on your computer so that the spreadsheet can be interpreted correctly.
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)